Johnson RYBREVANT

Beyond's analysis on Johnson RYBREVANT

• 2026-09-14 — Johnson & Johnson’s RYBREVANT plus chemotherapy shows record overall survival in EGFR exon20‑insertion lung cancer, signaling a potential new standard of care

Recent news mentioning Johnson RYBREVANT

• 2026-09-14 — Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Appears alongside

• EGFR

Browse the full archive →